Saturday, 17 October 2026
AI scribes face TGA scrutiny, Oral GLP-1 waitlist warning, Europe backs oral orforglipron
- 01
TGA finds eight AI scribes may require medical device regulation
Eight of 12 digital scribe products reviewed by the TGA had functions likely to meet the legal definition of a medical device, although none of their suppliers identified them as such. The regulator did not disclose which eight products were affected; two other products required further information and two appeared unlikely to qualify based on available information. The review found that some scribes went beyond transcription and documentation to generate clinical conclusions, recommendations or other outputs potentially affecting patient care. The TGA did not test product safety or performance, assess privacy protections or determine detailed regulatory compliance, and said the findings did not establish that products were unsafe or suppliers had breached the law. It will undertake targeted compliance activities and provide further guidance on the regulatory boundaries for digital scribes.
- 02
TGA warns oral GLP-1 waitlists may breach advertising laws
The TGA has warned that telehealth providers promoting waitlists for unapproved oral GLP-1 medicines could breach Australian advertising laws. Penalties can reach $18.2 million per offence. The source gives limited further detail about the warning.
- 03
European committee backs oral orforglipron for diabetes and weight management
The CHMP has recommended European marketing authorisation for Foundayo (orforglipron), an oral GLP-1 receptor agonist for type 2 diabetes and weight management. The film-coated tablets are intended for adults with insufficiently controlled type 2 diabetes, either as monotherapy when metformin is inappropriate or in combination with other diabetes medicines. The proposed weight-management indication covers adults with a BMI of at least 30 kg/m², or at least 27 kg/m² with a weight-related comorbidity, alongside a healthy diet and physical activity. Orforglipron had clinically relevant effects on glycaemic control and a beneficial effect on body weight, while the most common adverse effects were nausea, vomiting and diarrhoea. The European Commission will decide whether to grant marketing authorisation.
- 04
New GP toolkit targets frequently missed non-fatal strangulation
A new Australian toolkit supports GPs in assessing non-fatal strangulation and discussing it with patients using patient-centred, trauma-informed care. Developed by the University of Melbourne’s Centre for Excellence in Rural Sexual Health, it covers the mechanisms and acute or ongoing medical and psychosocial consequences, including artery damage, ischaemic injury, acquired brain injury and risk to life. The resource also addresses links with intimate partner violence and potential escalation to homicide or death. It says 25–50% of cases show no external injury and no signs or symptoms are pathognomonic, so clinical features must be assessed alongside the reported mechanism. It includes symptoms, red flags and guidance for conversations about non-consensual sex and strangulation.
via RACGP newsGP
- 05
GPs bridge months-long waits for adolescent mental health care
Australian GPs reported that adolescents waited an average of nearly two months to see psychologists and four months to see psychiatrists. In a survey of 190 GPs, more than 90% said long waits increased risks including worsening symptoms, treatment disengagement, feeling abandoned and reduced future help-seeking. Eighty per cent had seen increased presentations for adolescent depression or anxiety over the previous year, while more than 80% had increased appointments and support for young patients awaiting specialist care. GPs provided ongoing consultations, psychoeducation, lifestyle advice and recommendations for digital mental health resources while also managing clinical risk and supporting families. The findings come amid projections of a shortfall of at least 230 child and adolescent psychiatrists by 2028.
via RACGP newsGP
- 06
Rotating weekend birthing trial begins at two SA hospitals
A rotating birthing-unit trial has begun on weekends across Crystal Brook and Jamestown hospitals after workforce shortages temporarily suspended services earlier this year. Under the “one-term, one-site” model, the designated birthing suite alternates between the hospitals every one or two months. SA Health said both sites had not met its requirement for three separate doctors to be simultaneously available for emergency caesarean, anaesthetic and neonatal care, with clinicians covering multiple roles across sites no longer supported. Four local GPs raised concerns that effectively closing one unit during each rotation could increase handover errors and unintentional gaps. SA Health said local maternity teams would contact women due to give birth about the arrangements and that clear handovers would form an important part of the trial’s evaluation.
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.